234 related articles for article (PubMed ID: 21156732)
1. The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use.
Gravanis I; Ersbøll J; Skovlund E; Abadie E; Marty M; Pignatti F
Oncologist; 2010; 15(12):1335-43. PubMed ID: 21156732
[TBL] [Abstract][Full Text] [Related]
2. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
[TBL] [Abstract][Full Text] [Related]
3. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJ; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Osterborg A;
J Clin Oncol; 2010 Apr; 28(10):1749-55. PubMed ID: 20194866
[TBL] [Abstract][Full Text] [Related]
4. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
[TBL] [Abstract][Full Text] [Related]
5. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
Barth MJ; Czuczman MS
Future Oncol; 2013 Dec; 9(12):1829-39. PubMed ID: 24295413
[TBL] [Abstract][Full Text] [Related]
6. Ofatumumab in the treatment of chronic lymphocytic leukemia.
Tsimberidou AM
Drugs Today (Barc); 2010 Jul; 46(7):451-61. PubMed ID: 20683500
[TBL] [Abstract][Full Text] [Related]
7. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
Nightingale G
Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
[TBL] [Abstract][Full Text] [Related]
8. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.
O'Brien S; Osterborg A
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):361-8. PubMed ID: 21030349
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
10. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
Hoyle M; Crathorne L; Garside R; Hyde C
Health Technol Assess; 2011 May; 15 Suppl 1():61-7. PubMed ID: 21609654
[TBL] [Abstract][Full Text] [Related]
11. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.
Gupta IV; Jewell RC
Ann N Y Acad Sci; 2012 Aug; 1263():43-56. PubMed ID: 22830942
[TBL] [Abstract][Full Text] [Related]
12. Ofatumumab for the treatment of chronic lymphocytic leukemia.
Grosicki S
Expert Rev Hematol; 2015 Jun; 8(3):265-72. PubMed ID: 25882470
[TBL] [Abstract][Full Text] [Related]
13. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.
Wierda WG; Padmanabhan S; Chan GW; Gupta IV; Lisby S; Osterborg A;
Blood; 2011 Nov; 118(19):5126-9. PubMed ID: 21856867
[TBL] [Abstract][Full Text] [Related]
14. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
[TBL] [Abstract][Full Text] [Related]
15. Ofatumumab: chronic lymphocytic leukaemia: a last resort.
Prescrire Int; 2010 Oct; 19(109):201-3. PubMed ID: 21180369
[TBL] [Abstract][Full Text] [Related]
16. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
[TBL] [Abstract][Full Text] [Related]
17. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E
Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114
[TBL] [Abstract][Full Text] [Related]
18. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
Byrd JC; Peterson BL; Rai KR; Hurd D; Hohl R; Perry MC; Gockerman J; Nattam S; Larson RA
Leuk Lymphoma; 2009 Oct; 50(10):1589-96. PubMed ID: 19863336
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]